Table 3.
Results of the performance indicators on the quality of metastatic melanoma care – Univariate Analysis.
| Long-term outcomes | Advanced Melanoma:IIIB-IIIC (unresectable), IV | |
|---|---|---|
| Events1 (n) DOD/DEAD | Median MSS (95% CI) | |
| Melanoma-specific Survival (MSS) overall | 314/353 | 47 (41-53) |
| Melanoma-specific Survival (MSS) of pts. with local treatment | 132/147 | 42 (35-48) |
| Melanoma-specific Survival (MSS) of pts. with chemotherapy | 151/163 | 33 (27-38) |
| Melanoma-specific Survival (MSS) of pts. with immunotherapy | 126/137 | 50 (43-57) |
| MSS Immunotherapy: ANTI-PD-1 (Nivolumab/Pebrolizumab) | 17/18 | 70 (39-101) |
| MSS Immunotherapy: ANTI-CTLA4 (Ipilimumab) | 94/104 | 47 (37-56) |
| MSS Immunotherapy: ANTI-PD-1+ANTI-CTLA4 | 15/15 | 58 (26-90) |
| Melanoma-specific Survival (MSS) of pts. with target therapy | 129/147 | 44 (38-50) |
| MSS BRAFi: vemurafenib/dabrafenib | 91/107 | 40 (34-45) |
| MSS BRAFI+MEKI: cobimetinib/trametinib | 38/40 | 55 (49-61) |
1Event: number of deaths of the disease (DOD)/number of deaths for all causes (DEAD).